Medication info
Lyrica Capsule 150 mg (Pregabalin)

Lyrica Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Viatris
Appearance
A hard capsule with a white upper part and a white lower part containing white powder that is white or light yellow.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 200511058 · Approved 2005.06.14 · Insurance code 073400210

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial-onset seizures)
Who takes it
Adults · Children
Adult dose
This drug is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Because this drug is primarily eliminated by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or sufficient tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily eliminated by the kidneys as unchanged drug. Because the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: A supplemental dose refers to an additional dose administered as a single dose. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Importer
Viatris

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial-onset seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy, whether or not they are accompanied by secondary general symptoms. Additionally, it is effective in the treatment of fibromyalgia. It is used to improve multiple nerve-related disorders and pain.

How to take

Adult dose

This drug is administered orally, with or without food, as the total daily dose of pregabalin divided into 2 doses. Because this drug is primarily eliminated by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or sufficient tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily eliminated by the kidneys as unchanged drug. Because the clearance of this drug is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4 hours of hemodialysis. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the method of administration. b: A supplemental dose refers to an additional dose administered as a single dose. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if there are changes in mood or behavior during treatment, healthcare providers should be notified immediately. Individuals with allergies to any of the ingredients of this medication or those with genetic conditions such as galactose intolerance, lactase deficiency, and glucose-galactose malabsorption should not take this medication. Patients with diabetes may experience weight gain while taking this medication, necessitating adjustments in their blood sugar controlling medications. If severe allergic reactions such as angioedema occur, the medication should be discontinued immediately. Elderly patients may experience symptoms such as dizziness, drowsiness, loss of consciousness, and confusion while taking this medication and should exercise caution. When such symptoms arise, they should avoid driving or operating dangerous machinery. Temporary blurring or changes in vision may occur, and if symptoms are severe, it may be necessary to discontinue the medication. Suddenly stopping this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety; thus, it should be tapered off gradually according to a physician's guidance. Due to the potential for drug abuse or dependence, caution is advised for patients with a history of drug abuse, and they should consult healthcare professionals if unusual behavior occurs. Patients with impaired renal function may need dosage adjustments. Patients with cardiovascular diseases should be careful when taking this medication, especially patients with congestive heart failure who should take it cautiously. Care should be taken when using this medication in combination with opioids, as it may enhance central nervous system depression. Patients with respiratory diseases, neurological disorders, renal impairment, and elderly patients are at higher risk of severe respiratory depression and may need dose adjustments. During early pregnancy, there is a risk of fetal malformations, so it is best not to take this medication during pregnancy, and women of childbearing age should use effective contraception. This medication is excreted in breast milk, so breastfeeding should be avoided or a consultation with a physician should be obtained. This medication can cause dizziness and drowsiness, so it is safer to refrain from driving or operating dangerous machinery after taking it. Severe skin reactions are rare but can occur; if symptoms such as rash or swelling appear, the medication should be stopped immediately and healthcare providers notified. This medication has minimal pharmacokinetic interactions with other drugs; however, caution is advised as its effects may increase if taken with alcohol or central nervous system depressants. In cases of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate treatment at a hospital. Children, the elderly, and patients with impaired renal function need special care when taking this medication. Keep this medication out of the reach of children, and do not transfer it to another container.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 203 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • sexual paraesthesia
  • restlessness
  • anxiety
  • mood disturbance
  • emotional low
  • emotional high
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • numbness
  • ataxia
  • abnormal motor coordination
  • balance disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremor
  • dysarthria
  • paresthesia
  • sensory loss
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech impairment
  • myoclonus
  • reduced reflexes
  • motor abnormalities
  • psychomotor agitation
  • position-related dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing impairment
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye edema
  • vision reduction
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • change in depth perception of vision
  • strabismus
  • brightness of vision
  • dizziness
  • auditory hyperesthesia
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distention
  • constipation
  • dry mouth
  • flatulence
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • oliguria
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • loss of consciousness
  • mental disorder
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • mood disorder
  • drowsiness
  • state of confusion
  • depression
  • agitation
  • restlessness
  • seizures
  • shock
  • anaphylaxis-like symptoms
  • skin and mucous membrane syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Additionally, it is advisable to store it at room temperature between 15 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a white upper part and a white lower part containing white powder that is white or light yellow.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.